Age: 67.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Myasthenia gravis, Ophthalmological examination
Clinical narrative: Patient had myasthenia gravis and was seeing double; This spontaneous case was reported by a patient and describes the occurrence of MYASTHENIA GRAVIS (Patient had myasthenia gravis and was seeing double) in a 67-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 012A214 and 031M20A) for COVID-19 prophylaxis.     Concurrent medical conditions included Blood pressure high.   On 12-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 10-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced MYASTHENIA GRAVIS (Patient had myasthenia gravis and was seeing double) (seriousness criterion medically significant). The patient was treated with PYRIDOSTIGMINE for Myasthenia gravis, at a dose of 60 milligram three times a day. At the time of the report, MYASTHENIA GRAVIS (Patient had myasthenia gravis and was seeing double) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Ophthalmological examination: 20/16.         Patient had been taking a blood pressure medication for high blood pressure. It was reported that 3 weeks after the patient received the first dose of the mRNA-1273 vaccine, he started to have visual problems and had a loss of vision or 45 seconds to a minute. Brain scan did not show abnormalities. After the second dose of the vaccine, he still had a little vision trouble. A year after getting the second shot the patient started seeing double on the road and thought of having a stroke. After consultation with an ophthalmologist and a neurologist, the patient was diagnosed with myasthenia gravis. Patient was told to get the other shots because if catched COVID-19 it could kill patient because the medicine had patient's immune system down.   Company comment: This spontaneous case report concerns a 67-year-old male patient with no relevant medical history, who experienced serious (medically significant) unexpected event of Myasthenia gravis. Reportedly, 3 weeks after the patient had received the first dose of the mRNA-1273 vaccine, he started to have visual problems and had a loss of vision or 45 seconds to a minute. Brain scan did not show abnormalities. After the patient received the second dose of the mRNA-1273 vaccine, he still had vision trouble. Finally, one year after the second vaccination, the patient started to have double vision and neurologist confirmed the diagnosis of myasthenia gravis. The patient was treated with pyridostigmine. At the time of this report, no further details were available. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.   This case was linked to MOD-2022-656449 (Patient Link).; Sender's Comments: This spontaneous case report concerns a 67-year-old male patient with no relevant medical history, who experienced serious (medically significant) unexpected event of Myasthenia gravis. Reportedly, 3 weeks after the patient had received the first dose of the mRNA-1273 vaccine, he started to have visual problems and had a loss of vision or 45 seconds to a minute. Brain scan did not show abnormalities. After the patient received the second dose of the mRNA-1273 vaccine, he still had vision trouble. Finally, one year after the second vaccination, the patient started to have double vision and neurologist confirmed the diagnosis of myasthenia gravis. The patient was treated with pyridostigmine. At the time of this report, no further details were available. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.